Ładuje się......
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Society for Clinical Investigation
2002
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC151148/ https://ncbi.nlm.nih.gov/pubmed/12370270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI15634 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|